NDI notifications: when your US supplement ingredient needs one

In the US, most supplement ingredients can go to market without telling the FDA in advance. But there is an important exception — the New Dietary Ingredient, or NDI — and getting it wrong can mean an ingredient is considered adulterated and cannot legally be sold. With the FDA signalling it intends to finalize its long-pending NDI guidance, this is a good moment to understand the rule.

What an NDI is

Under DSHEA, dietary ingredients are split by history. An ingredient marketed in the US before a cut-off tied to DSHEA's enactment is treated as a pre-existing ingredient. A New Dietary Ingredient is, broadly, one that was not marketed in the US before that point.

The category matters because new ingredients carry an extra safety step that pre-existing ones do not.

When a notification is required

If an ingredient is an NDI, the manufacturer or distributor generally must submit a notification to the FDA before marketing it — demonstrating a basis for concluding the ingredient is reasonably expected to be safe under the product's conditions of use. The notification goes in ahead of time, and the FDA has a window to review it.

There is an exception: if the new dietary ingredient has been present in the food supply as an article used for food, in a form that has not been chemically altered, a notification may not be required. That carve-out is narrower than it sounds, and whether it applies is exactly the kind of judgement that needs care.

What the notification involves

An NDI notification is a safety dossier. It identifies the ingredient precisely, describes the conditions of use — the product, the dose, the population — and presents the evidence supporting a reasonable expectation of safety at that use level.

The identity of the ingredient is central: the exact substance, its source, and how it is produced all matter, because a different form or process can be a different ingredient for these purposes.

Why it is a go/no-go question

For a manufacturer, NDI status is a gate that belongs at the very start of development. Building a product around an ingredient that turns out to require a notification — one you have not made — means the product cannot legally launch until the situation is resolved. Discovering this late, after formulation and packaging, is an expensive way to learn the rule.

The smart sequence is to establish each ingredient's status before committing to it, not after.

Why this is a live topic

The NDI area has been unsettled for years, with draft guidance that was never finalized and persistent industry questions about how the rules apply to modern ingredients — botanicals, ingredients made by new processes, and substances that did not exist when DSHEA was written. The FDA has indicated it intends to finalize NDI guidance, which would give manufacturers clearer expectations.

Because the NDI framework is actively evolving and guidance is being updated, confirm the current FDA position and requirements for your specific ingredients rather than relying on a general summary.

Building status into formulation

The practical defence is to treat each ingredient's regulatory status — including whether it is a new dietary ingredient and whether a notification exists or is needed — as a property of the ingredient, visible as you formulate. When that status travels with the ingredient, a notification-triggering choice surfaces while the product is still on the screen, not after it is built.

This mirrors how novel ingredient status works in other markets: the question "can we even use this?" is answered before development effort goes in.

The takeaway

A New Dietary Ingredient may require a pre-market safety notification to the FDA before it can be used in a US supplement — a genuine go/no-go question driven by the ingredient's history, identity, and conditions of use. With the FDA moving to finalize NDI guidance, the discipline that protects manufacturers is the same as ever: check each ingredient's status before you formulate around it.

Lemoniq treats each ingredient's regulatory status as a property of the ingredient, so a notification-triggering choice surfaces as you formulate — before development goes any further. We solve this exact problem. See how it works